# Eli Lilly to acquire POINT Biopharma for radioligand therapies

Eli Lilly and Company announced a definitive agreement to acquire POINT Biopharma, a radiopharmaceutical company with a pipeline of radioligand therapies for cancer. The acquisition includes POINT's manufacturing campus in Indianapolis and R&D center in Toronto.

- Type: Acquisition
- Announced: 2023-10-03
- Where: Indianapolis, Indiana, United States
- Status: announced
- Products: radioligand therapies, radiopharmaceuticals
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Eli Lilly and Company](https://endata.com/companies/16522.md) (acquirer)
- [POINT Biopharma Global Inc.](https://endata.com/companies/71729.md) (target)

## Sources

- [investor.lilly.com](https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-point-biopharma-expand-oncology-capabilities-next), 2023-10-03: "We are excited by the potential of this emerging modality and see the acquisition of POINT as the beginning of our investment in developing multiple meaningful radioligand medicines for hard-to-treat cancers."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.